Q-omics provides the consensus-scored PRR32 profile across patient tissues and cancer cell-line models. PRR32 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PRR32 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, PRR32 RNA expression shows 7,311 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight KICH, THCA, and SARC as cancer lineages where PRR32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR32 survival associations across molecular data types. PRR32 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR32 RNA expression–survival associations across cancer types. High PRR32 expression shows unfavorable associations in KICH, KIRP, HNSC, LGG and BRCA, but favorable associations in LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PRR32 RNA expression.
This table summarizes PRR32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRR32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR32 shows lower tumor expression in HNSC, KICH and LIHC and higher tumor expression in THCA, LUAD and BRCA. The THCA box plot shows higher PRR32 RNA expression in tumor versus normal tissue (log2 FC = +0.614, t-test p < 0.001).
This table shows molecular features associated with PRR32 in patient tissues and cancer cell lines. In patient samples, PRR32 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
